AmplifyBio

AmplifyBio

AmplifyBio is a contract research organization (CRO) and manufacturing organization (CDMO) based in Columbus, Ohio, that connects early R&D, safety assessments, and manufacturing to advance drug development (per the firm, 2025). The firm operates as a single, integrated service provider for advanced therapies, spanning preclinical testing through clinical-scale production. No founding year, principal names, or wealth origin are publicly disclosed. AmplifyBio's service mix covers toxicology, bioanalysis, and cell and gene therapy manufacturing. The firm does not publicly disclose asset-class allocations, portfolio investments, or geographic footprint beyond its Columbus headquarters. It cites no named clients, deals, or co-investors in its available materials. The firm's website lists no investment stages or fund structures. No team size, additional offices, or adjacent philanthropic vehicles are disclosed. No recent operational events from the last 24 months are verifiable via public sources. The firm's limited public presence prevents independent assessment of scale or trajectory. AmplifyBio's structure—as a contract service provider rather than a capital allocator—distinguishes it from typical family offices. Without disclosed principals, AUM, or investment activity, its classification as a family office remains unconfirmed. Succession, governance, and ownership relationships are not public.